82 related articles for article (PubMed ID: 12523495)
1. Perazine as a potent inhibitor of human CYP1A2 but not CYP3A4.
Wójcikowski J; Pichard-Garcia L; Maurel P; Daniel WA
Pol J Pharmacol; 2002; 54(4):407-10. PubMed ID: 12523495
[TBL] [Abstract][Full Text] [Related]
2. Effects of cytochrome P-450 inducers on the perazine metabolism in a primary culture of human hepatocytes.
Wójcikowski J; Pichard-Garcia L; Maurel P; Daniel WA
Pol J Pharmacol; 2003; 55(4):655-8. PubMed ID: 14581727
[TBL] [Abstract][Full Text] [Related]
3. Perazine at therapeutic drug concentrations inhibits human cytochrome P450 isoenzyme 1A2 (CYP1A2) and caffeine metabolism--an in vitro study.
Wójcikowski J; Daniel WA
Pharmacol Rep; 2009; 61(5):851-8. PubMed ID: 19904008
[TBL] [Abstract][Full Text] [Related]
4. Autoinduction of the metabolism of phenothiazine neuroleptics in a primary culture of human hepatocytes.
Wójcikowski J; Maurel P; Daniel WA
Pharmacol Rep; 2012; 64(6):1578-83. PubMed ID: 23406770
[TBL] [Abstract][Full Text] [Related]
5. The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes.
Wójcikowski J; Pichard-Garcia L; Maurel P; Daniel WA
Eur Neuropsychopharmacol; 2004 May; 14(3):199-208. PubMed ID: 15056479
[TBL] [Abstract][Full Text] [Related]
6. Variation in the Response of Clozapine Biotransformation Pathways in Human Hepatic Microsomes to CYP1A2- and CYP3A4-selective Inhibitors.
Murray M; Zhang WV; Edwards RJ
Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):388-395. PubMed ID: 29155491
[TBL] [Abstract][Full Text] [Related]
7. Role of human microsomal and human complementary DNA-expressed cytochromes P4501A2 and P4503A4 in the bioactivation of aflatoxin B1.
Gallagher EP; Wienkers LC; Stapleton PL; Kunze KL; Eaton DL
Cancer Res; 1994 Jan; 54(1):101-8. PubMed ID: 8261428
[TBL] [Abstract][Full Text] [Related]
8. [The combined effect of isoniazid and rifampicin on the activities of CYP4501A2 and CYP4503A4 in primary hepatocytes from healthy human adults].
Liu ZW; Hu ZH; Cai YY
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Nov; 28(11):785-8. PubMed ID: 16324277
[TBL] [Abstract][Full Text] [Related]
9. Determination of cytochrome P450 1A2 and cytochrome P450 3A4 induction in cryopreserved human hepatocytes.
Roymans D; Van Looveren C; Leone A; Parker JB; McMillian M; Johnson MD; Koganti A; Gilissen R; Silber P; Mannens G; Meuldermans W
Biochem Pharmacol; 2004 Feb; 67(3):427-37. PubMed ID: 15037195
[TBL] [Abstract][Full Text] [Related]
10. Azide inhibits human cytochrome P -4502E1, 1A2, and 3A4.
Salmela KS; Tsyrlov IB; Lieber CS
Alcohol Clin Exp Res; 2001 Feb; 25(2):253-60. PubMed ID: 11236840
[TBL] [Abstract][Full Text] [Related]
11. Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites.
Sutton D; Butler AM; Nadin L; Murray M
J Pharmacol Exp Ther; 1997 Jul; 282(1):294-300. PubMed ID: 9223567
[TBL] [Abstract][Full Text] [Related]
12. Induction of CYP1A by benzo[k]fluoranthene in human hepatocytes: CYP1A1 or CYP1A2?
Liu N; Zhang QY; Vakharia D; Dunbar D; Kaminsky LS
Arch Biochem Biophys; 2001 May; 389(1):130-4. PubMed ID: 11370663
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous assessment of cytochrome P450 activity in cultured human hepatocytes for compound-mediated induction of CYP3A4, CYP2B6, and CYP1A2.
Rhodes SP; Otten JN; Hingorani GP; Hartley DP; Franklin RB
J Pharmacol Toxicol Methods; 2011; 63(3):223-6. PubMed ID: 21111054
[TBL] [Abstract][Full Text] [Related]
14. The olivacine derivative s 16020 (9-hydroxy-5,6-dimethyl-N-[2-(dimethylamino)ethyl)-6H-pyrido(4,3-B)-carbazole-1-carboxamide) induces CYP1A and its own metabolism in human hepatocytes in primary culture.
Pichard-Garcia L; Weaver RJ; Eckett N; Scarfe G; Fabre JM; Lucas C; Maurel P
Drug Metab Dispos; 2004 Jan; 32(1):80-8. PubMed ID: 14709624
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of luciferin-isopropyl acetal as a CYP3A4 substrate for human hepatocytes: effects of organic solvents, cytochrome P450 (P450) inhibitors, and P450 inducers.
Li AP
Drug Metab Dispos; 2009 Aug; 37(8):1598-603. PubMed ID: 19451401
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites.
Botsch S; Gautier JC; Beaune P; Eichelbaum M; Kroemer HK
Mol Pharmacol; 1993 Jan; 43(1):120-6. PubMed ID: 8423765
[TBL] [Abstract][Full Text] [Related]
17. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes.
Hellum BH; Hu Z; Nilsen OG
Basic Clin Pharmacol Toxicol; 2007 Jan; 100(1):23-30. PubMed ID: 17214607
[TBL] [Abstract][Full Text] [Related]
18. Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture.
Dickmann LJ; Patel SK; Rock DA; Wienkers LC; Slatter JG
Drug Metab Dispos; 2011 Aug; 39(8):1415-22. PubMed ID: 21555507
[TBL] [Abstract][Full Text] [Related]
19. An 'all-inclusive' 96-well cytochrome P450 induction method: measuring enzyme activity, mRNA levels, protein levels, and cytotoxicity from one well using cryopreserved human hepatocytes.
Halladay JS; Wong S; Khojasteh SC; Grepper S
J Pharmacol Toxicol Methods; 2012; 66(3):270-5. PubMed ID: 22809809
[TBL] [Abstract][Full Text] [Related]
20. The kinetics of aflatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4.
Gallagher EP; Kunze KL; Stapleton PL; Eaton DL
Toxicol Appl Pharmacol; 1996 Dec; 141(2):595-606. PubMed ID: 8975785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
